NCI Committed to Increasing Minority Participation in Clinical Trials

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 7
Volume 4
Issue 7

BETHESDA, Md--Acting NCI Director Edward Sondik announced that the institute is committed to increasing participation of minorities in clinical trials. However, cancer researchers have had only limited success in this effort, he said.

BETHESDA, Md--Acting NCI Director Edward Sondik announced thatthe institute is committed to increasing participation of minoritiesin clinical trials. However, cancer researchers have had onlylimited success in this effort, he said.

Dr. Sondik's remarks were made at a meeting of a new coalition,the Intercultural Cancer Council, sponsored by Baylor Collegeof Medicine, the Susan G. Komen Breast Cancer Foundation, M.D.Anderson Cancer Center, Howard University Hospital, the AmericanCancer Society, and Kellogg Company.

Recent Videos
The pediatric care wing of the Jack & Sheryl Morris Cancer Center is intended to accommodate the physical and emotional needs of younger patients with cancer.
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.